research use only
Cat.No.S2422
| Related Targets | Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism |
|---|---|
| Other AGEs Inhibitors | Azeliragon (TTP488) |
|
In vitro |
DMSO
: 56 mg/mL
(199.77 mM)
Ethanol : 2 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 280.32 | Formula | C18H16O3 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 35212-22-7 | Download SDF | Storage of Stock Solutions |
|
|
| Targets/IC50/Ki |
advanced glycation end products (AGE)
|
|---|---|
| In vitro |
Ipriflavone (Osteofix) regulates the differentiation and biosynthetic properties of human bone marrow stromal osteoprogenitor cells (BMC) by enhancing the expression of some important matrix proteins and facilitating the mineralization process. Treatment at 10 μM significantly inhibits advanced glycation end products (AGE) enhanced bone resorption in cultured mouse unfractionated bone cells. In addition, it potently enhances calcium uptake by duodenal cells. This compound inhibits the proliferation and DNA synthesis of MDA-231 cells in a dose-dependent manner, and blocks the ligand-induced phosphorylation of Tyr845 of the EGFR. Treatment at 50 μM does not induce apoptosis of MDA-231 cells.
|
| In vivo |
Oral administration of Ipriflavone (Osteofix) at 12 mg but not 6 mg significantly inhibits the development of new osteolytic bone metastases of MDA-231 cells, suppresses the progression of established osteolytic lesions, and reduces the number of osteoclasts adjacent to cancer cells in bone metastases. Consistent with the in vitro activity, treatment with this compound at 6 or 12 mg/day significantly inhibits tumor growth of MDA-231 xenografts with 25% and 45% reductions by volume and 47% and 63% by weight, respectively, compared to untreated mice, and prolongs the life of tumor-bearing mice. LD50: Mice >2.5g/kg (i.p.), >5g/kg (s.c.), >10g/kg (i.g.); Rats >2.5g/kg (i.p.), >5g/kg (s.c.), >10g/kg (i.g.)
|
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.